methylcellulose
Dietary Supplement2.5 and 5 gm Methylcelllose heated to create a gel
Other names: Benecel
NCT Number: NCT06551961
To determine the effect on tolerance and gas production from chronic feeding of fermentable fibre (inulin) incorporated into a gel forming fibre (methylcellulose) compared with placebo (maltodextrin)
Interested in participating?
Request Info18 year–65 year
All sexes
Interventional
Not applicable
Nottingham Digestive Disease Centre, Nottingham, Nottinghamshire, United Kingdom
Our challenge is to understand how various dietary fibres interact to alter colonic fermentation of FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides and polyols) with the aim of reducing gaseous distension of the colon and hence symptoms. Our previous studies have shown how psyllium, a gel forming natural fibre can reduce gas production induced by a dietary FODMAP inulin when it reaches the colon. The investigators are exploiting a range of food grade modified celluloses which can form gels at body temperature to perform human studies to explore whether the beneficial effect of psyllium is unique or will be found with all gelling substances 2.
The investigators have completed a study using a modified methylcellulose which was shown to be non-inferior to psyllium.
Our previous studies point to the importance of habitual FODMAP intake which is likely to alter the microbiota, selecting those that can efficiently utilise fructans. The investigators want to understand whether chronic feeding of inulin along with methylcellulose, a gel-forming dietary fibre which persists in the colon, will significantly alter the tolerance to inulin relative to chronic feeding of inulin with a suitable placebo maltodextrin. Maltodextrin is rapidly absorbed in the small bowel and therefore has no effect on colonic fermentation. The investigators plan to run a chronic feeding study in IBS patients and wish to ascertain tolerability of repeated use as previous studies have only provided single doses.
With this in mind, the investigators plan to provide inulin and methylcellulose for daily consumption by healthy adults for a period of two weeks. The intervention will be divided into 3 portions to be taken before breakfast, lunch and supper. In week 1, the portions will contain 2.5 g of both inulin and methylcellulose in 62.5 mL water. In week 2, the portions will contain 5.0 g of both inulin and methylcellulose in 125 mL water. The participants will also follow the same chronic feeding schedule but with a maltodextrin placebo as opposed to methylcellulose, with randomisation of study schedule taking place at screening.
The investigators will use MRI at baseline and at 2 weeks to assess changes in colonic volume and transit utilising high MRI contrast capsules54. The investigators will collect stool samples at baseline and after 1 and 2 weeks of chronic feeding for each study intervention to monitor the expected changes in microbiota. The primary objective is to assess the fermentation of inulin given as a single 15g with or without methylcellulose from the breath hydrogen response at baseline and after the 2 weeks feeding. .
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
2.5 and 5 gm Methylcelllose heated to create a gel
Other names: Benecel
2.5 and 5 gm inulin powder dissolved in water
2.5 and 5gm maltodextrin dissolved in water
Other names: Glusidex
Time frame: 0-6 hours
Area under curve (AUC) from time 0-6 hours (AUC 0-6) of breath hydrogen (ppm.hour) after consumption of inulin intake.
Time frame: 14 days
Time frame: 0-24 hours
Time frame: 0- 6 hours
Time for breath hydrogen to rise > 10ppm over baseline
Time frame: 0-7 days
assessed by marker transit
Time frame: 1 and 2 weeks post dosing
16s DNA analysis
Contact information is provided by the study sponsor or research team.
Alsion Thorpe, MD
CONTACT
Sponsor
CONTACT
University of Nottingham
Other
A Randomised Placebo Controlled Trial of Chronic Feeding of INuliN And Methylcellulose On Colonic fermentatioN
Acronym: CINNAMON
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01887834
Carbohydrate Metabolism, Inborn Errors, Colitis, Mucous
Toronto, Ontario, Canada
View Trial DetailsNCT00779493
Abdominal Pain, Carbohydrate Metabolism, Inborn Errors
Los Angeles, California, United States
View Trial DetailsNCT01176227
Carbohydrate Metabolism, Inborn Errors, Colitis, Mucous
Toronto, Ontario, Canada
View Trial DetailsNCT06801184
Colonic Diseases, Colonic Diseases, Functional
Lyon, France
View Trial Details